Connective tissue growth factor in tumor pathogenesis

Fibrogenesis and Tissue Repair

Volumn 5, Issue SUPPL.1, 2012, Pages

  Jacobson, Annica ^a   Cunningham, Janet L ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; FG 3019; SEROTONIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CARCINOGENESIS; CARCINOID; COLORECTAL CANCER; ENDOCRINE TUMOR; ENTEROCHROMAFFIN LIKE CELL CARCINOID; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; ILEUM CARCINOID; LUNG CANCER; MYOFIBROBLAST; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; TUMOR CELL; TUMOR GROWTH;

EID: 84880572506     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-5-S1-S8     Document Type: Article

References (63)

1. Ivkovic S, Yoon BS, Popoff SN, Safadi FF, Libuda DE, Stephenson RC, Daluiski A, Lyons KM. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003, 130:2779-2791. 10.1242/dev.00505, 3360973, 12736220.
2. Crawford LA, Guney MA, Oh YA, Deyoung RA, Valenzuela DM, Murphy AJ, Yancopoulos GD, Lyons KM, Brigstock DR, Economides A, Gannon M. Connective tissue growth factor (CTGF) inactivation leads to defects in islet cell lineage allocation and beta-cell proliferation during embryogenesis. Mol Endocrinol 2009, 23:324-336. 2654514, 19131512.
3. Doherty HE, Kim HS, Hiller S, Sulik KK, Maeda N. A mouse strain where basal connective tissue growth factor gene expression can be switched from low to high. PLoS One 2010, 5:e12909. 10.1371/journal.pone.0012909, 2943916, 20877562.
4. Grotendorst GR, Duncan MR. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. Faseb J 2005, 19:729-738. 10.1096/fj.04-3217com, 15857887.
5. Yang DH, Kim HS, Wilson EM, Rosenfeld RG, Oh Y. Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells. J Clin Endocrinol Metab 1998, 83:2593-2596. 10.1210/jc.83.7.2593, 9661651.
6. de Winter P, Leoni P, Abraham D. Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein. Growth Factors 2008, 26:80-91. 10.1080/08977190802025602, 18428027.
7. Dziadzio M, Usinger W, Leask A, Abraham D, Black CM, Denton C, Stratton R. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. Qjm 2005, 98:485-492. 10.1093/qjmed/hci078, 15955800.
8. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004, 27:1164-1170. 10.2337/diacare.27.5.1164, 15111539.
9. Grotendorst GR, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. Faseb J 2004, 18:469-479. 10.1096/fj.03-0699com, 15003992.
10. Kubota S, Hattori T, Shimo T, Nakanishi T, Takigawa M. Novel intracellular effects of human connective tissue growth factor expressed in Cos-7 cells. FEBS Lett 2000, 474:58-62. 10.1016/S0014-5793(00)01573-8, 10828451.
11. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005, 65:8887-8895. 10.1158/0008-5472.CAN-05-1702, 16204060.
12. Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, Nishida K, Kawai A, Nakanishi T, Takigawa M, Inoue H. Expression of connective tissue growth factor in cartilaginous tumors. Cancer 2000, 89:1466-1473. 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G, 11013359.
13. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ, Xie D. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2007, 2:e534. 10.1371/journal.pone.0000534, 1888724, 17579708.
14. Kikuchi R, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, Hirohashi S, Inazawa J, Imoto I. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res 2007, 67:7095-7105. 10.1158/0008-5472.CAN-06-4567, 17671176.
15. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751. 10.1038/onc.2010.215, 3176718, 20531305.
16. Burns WC, Thomas MC. The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology. Expert Rev Mol Med 2010, 12:e17.
17. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010, 29:6485-6498. 10.1038/onc.2010.377, 3076082, 20802523.
18. Wang B, Herman-Edelstein M, Koh P, Burns W, Jandeleit-Dahm K, Watson A, Saleem M, Goodall GJ, Twigg SM, Cooper ME, Kantharidis P. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010, 59:1794-1802. 10.2337/db09-1736, 2889781, 20393144.
19. Secker GA, Shortt AJ, Sampson E, Schwarz QP, Schultz GS, Daniels JT. TGFbeta stimulated re-epithelialisation is regulated by CTGF and Ras/MEK/ERK signalling. Exp Cell Res 2008, 314:131-142. 10.1016/j.yexcr.2007.09.001, 17915216.
20. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999, 19:2958-2966. 84090, 10082563.
21. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999, 248:44-57. 10.1006/excr.1999.4456, 10094812.
22. Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, Wong C, Kaper F, Sutphin P, Nacamuli R, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2006, 66:5816-5827. 10.1158/0008-5472.CAN-06-0081, 16740721.
23. Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, Feazell J, Yang GP, Koong A, Giaccia AJ. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 2009, 69:775-784. 10.1158/0008-5472.CAN-08-0987, 2747032, 19179545.
24. Luft FC. CCN2, the connective tissue growth factor. J Mol Med 2008, 86:1-3. 10.1007/s00109-007-0287-x, 18080105.
25. Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci 2008, 15:675-685. 10.1007/s11373-008-9264-9, 18622762.
26. Wahab N, Cox D, Witherden A, Mason RM. Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via up-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1). Biochem J 2007, 406:131-138. 10.1042/BJ20061817, 1948989, 17489738.
27. Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, Kusuanco D, Marchevsky A, McKenna R, Koeffler HP. Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res 2006, 4:591-598. 10.1158/1541-7786.MCR-06-0029, 16877704.
28. Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, Lin MT, Chang KJ, Kuo ML. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 2009, 69:3482-3491. 10.1158/0008-5472.CAN-08-2524, 19351859.
29. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM, Liang JT, Lee PH, Chang KJ, et al. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 2005, 128:9-23. 10.1053/j.gastro.2004.10.007, 15633118.
30. Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, Tong XJ, Xie D. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem 2007, 282:36571-36581. 10.1074/jbc.M704141200, 17951630.
31. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004, 1014:13-27. 10.1196/annals.1294.002, 15153416.
32. Cunningham JL, Tsolakis AV, Jacobson A, Janson ET. Connective tissue growth factor (CTGF) expression in endocrine tumors is associated with high stromal expression of alpha-smooth muscle actin. Eur J Endocrinol 2010, 163:691-697. 10.1530/EJE-10-0420, 20660557.
33. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961, 14:901-912. 10.1002/1097-0142(196109/10)14:5<901::AID-CNCR2820140502>3.0.CO;2-Q, 13771655.
34. Hallen A. Fibrosis in the carcinoid syndrome. Lancet 1964, 1:746-747.
35. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol 2004, 99:2466-2478. 10.1111/j.1572-0241.2004.40507.x, 15571597.
36. Sakai D, Murakami M, Kawazoe K, Tsutsumi Y. Ileal carcinoid tumor complicating carcinoid heart disease and secondary retroperitoneal fibrosis. Pathol Int 2000, 50:404-411. 10.1046/j.1440-1827.2000.01053.x, 10849330.
37. Gupta A, Saibil F, Kassim O, McKee J. Retroperitoneal fibrosis caused by carcinoid tumour. Q J Med 1985, 56:367-375.
38. Day RM, Agyeman AS, Segel MJ, Chevere RD, Angelosanto JM, Suzuki YJ, Fanburg BL. Serotonin induces pulmonary artery smooth muscle cell migration. Biochem Pharmacol 2006, 71:386-397. 10.1016/j.bcp.2005.10.035, 1831537, 16316635.
39. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005, 111:1517-1522. 10.1161/01.CIR.0000159356.42064.48, 15781732.
40. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med 2003, 348:1005-1015. 10.1056/NEJMoa021451, 12637610.
41. Rajamannan NM, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards WD, Tajik J, Schwartz RS. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001, 10:827-831.
42. Rameshwar P, Oh HS, Yook C, Gascon P, Chang VT. Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. Acta Haematol 2003, 109:1-10. 10.1159/000067268, 12486316.
43. Nilsson J, von Euler AM, Dalsgaard CJ. Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985, 315:61-63. 10.1038/315061a0, 2581142.
44. Katayama I, Nishioka K. Substance P augments fibrogenic cytokine-induced fibroblast proliferation: possible involvement of neuropeptide in tissue fibrosis. J Dermatol Sci 1997, 15:201-206. 10.1016/S0923-1811(97)00608-7, 9302648.
45. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R, Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998, 28:1038-1049. 10.1046/j.1365-2362.1998.00397.x, 9893017.
46. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992, 52:1006-1012.
47. Nilsson O, Wangberg B, McRae A, Dahlstrom A, Ahlman H. Growth factors and carcinoid tumours. Acta Oncol 1993, 32:115-124. 10.3109/02841869309083899, 8323752.
48. Nilsson O, Wangberg B, Theodorsson E, Skottner A, Ahlman H. Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?. Int J Cancer 1992, 51:195-203. 10.1002/ijc.2910510206, 1314781.
49. Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R, Fehmann HC. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest 2000, 30:729-739. 10.1046/j.1365-2362.2000.00700.x, 10964166.
50. Zhang PJ, Furth EE, Cai X, Goldblum JR, Pasha TL, Min KW. The role of beta-catenin, TGF beta 3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Hum Pathol 2004, 35:670-674. 10.1016/j.humpath.2003.12.010, 15188132.
51. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. Faseb J 1999, 13:1774-1786.
52. Kothapalli D, Frazier KS, Welply A, Segarini PR, Grotendorst GR. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ 1997, 8:61-68.
53. Hahn A, Heusinger-Ribeiro J, Lanz T, Zenkel S, Goppelt-Struebe M. Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J Biol Chem 2000, 275:37429-37435. 10.1074/jbc.M000976200, 10976101.
54. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, Mann DA. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 2006, 169:861-876. 10.2353/ajpath.2006.050767, 1698820, 16936262.
55. Svejda B, Kidd M, Giovinazzo F, Eltawil K, Gustafsson BI, Pfragner R, Modlin IM. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer 2010, 116:2902-2912. 10.1002/cncr.25049, 20564397.
56. Kidd M, Modlin IM, Shapiro MD, Camp RL, Mane SM, Usinger W, Murren JR. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol 2007, 13:5208-5216.
57. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, Eriksson B, Janson ET. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009, 89:302-307. 10.1159/000179900, 19176944.
58. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987, 5:1502-1522.
59. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, Johansson V, Schersten T, Ahlman H. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996, 20:892-899; discussion 899. 10.1007/s002689900136, 8678968.
60. Kaltsas G, Cunningham J, Falkmer S, Grimelius L, Tsolakis A. Expression of connective tissue growth factor and insulin growth factor 1 in normal and neoplastic gastrointestinal neuroendocrine cells and their clinicopathological significance. Endocrine-Related Cancer
61. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 2006, 5:1108-1116. 10.1158/1535-7163.MCT-05-0516, 16731742.
62. Cheng WF, Chang MC, Sun WZ, Lee CN, Lin HW, Su YN, Hsieh CY, Chen CA. Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther 2008, 15:1007-1016. 10.1038/gt.2008.25, 18356819.
63. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, Syu MH, Hsieh CY, Cheng WF. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010, 18:1233-1243. 10.1038/mt.2010.34, 2889744, 20372107.